Patents Assigned to Merck Patent GmbH
  • Patent number: 11491162
    Abstract: A combination includes as a first active ingredient 6-fluoro-2-(4-morpholin-4-ylmethyl-phenyl)-quinoline-4-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide or a prodrug or pharmaceutically acceptable salt thereof and as a second active ingredient pyronaridine or a prodrug or pharmaceutically acceptable salt thereof. Also, a combination includes three antimalarial active ingredients, namely of 6-fluoro-2-(4-morpholin-4-ylmethyl-phenyl)-quinoline-4-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide or a prodrug or salt thereof, pyronaridine or pharmaceutically acceptable salt thereof, and artemisinin or derivatives thereof. Further, pharmaceutical compositions include such combination. The combinations and pharmaceutical compositions are useful for the treatment and/or prevention of malaria.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: November 8, 2022
    Assignee: Merck Patent GmbH
    Inventors: Thomas Spangenberg, Claude Oeuvray, Nada Abla
  • Patent number: 11491153
    Abstract: The present invention provides methods of treating cancer using pyrimidine and pyridine compounds which are inhibitors of Bruton's tyrosine kinase (BTK).
    Type: Grant
    Filed: March 5, 2020
    Date of Patent: November 8, 2022
    Assignee: Merck Patent GmbH
    Inventors: Bayard R. Huck, Samantha M. Goodstal, Claude Gimmi-McKim
  • Publication number: 20220349246
    Abstract: A switchable optical device including in this order a first substrate, a first conductive layer, a switchable layer, a second conductive layer and a second substrate, which device further contains one or both of the following: i) the first conductive layer contains a first contact zone and a second contact zone, wherein the first contact zone is electrically insulated from the second contact zone and the switchable optical device contains an electrical interconnect for electrically connecting the second contact zone of the first conductive layer the second conductive layer, ii) the switchable optical device contains at least one further sheet which is laminated to the first substrate and/or the second substrate, wherein first substrate, second substrate and the at least one further sheet have essentially the same thermal expansion coefficient. A switchable glazing unit containing at least one glass pane and at least one switchable optical device.
    Type: Application
    Filed: June 29, 2020
    Publication date: November 3, 2022
    Applicant: MERCK PATENT GMBH
    Inventors: Michael JUNGE, Michael UKELIS, Manfred ECKERT, Rainer NEEFF
  • Publication number: 20220348640
    Abstract: The invention provides a method for eluting a monoclonal antibody from a Protein A affinity chromatography column to which the monoclonal antibody is bound comprising a) contacting the affinity chromatography column with an elution buffer comprising a poly (ethylene glycol) polymer; b) collecting one or more fractions containing the monoclonal antibody obtained from step (a) c) combining the fractions obtained from step (b) to form an elution product pool.
    Type: Application
    Filed: October 1, 2020
    Publication date: November 3, 2022
    Applicant: Merck Patent GmbH
    Inventors: Christoph KORPUS, Supriyadi HAFIZ
  • Publication number: 20220348608
    Abstract: A method for purifying a target protein from a cell culture sample containing the target protein, viral compounds and other impurities, by affinity chromatography virus inactivation and optionally other purifications the affinity chromatography involving a) loading an affinity chromatography column with the cell culture sample thereby binding the target protein to the affinity chromatography column; b) eluting the target protein from the affinity chromatography column by contacting the affinity chromatography column with an elution buffer having a pH<6 and comprising an excipient, wherein the excipient is disaccharides, polyols or poly (ethylene glycol) polymers; c) collecting one or more fractions containing the target protein obtained from (b); d) potentially combining the fractions obtained from (c) to form an elution product pool, and wherein the virus inactivation involves e) incubating the elution product pool at a pH from 2.5 to 4.5.
    Type: Application
    Filed: October 1, 2020
    Publication date: November 3, 2022
    Applicant: MERCK PATENT GMBH
    Inventors: Christoph KORPUS, Supriyadi HAFIZ, Alexandra KROG, Romas SKUDAS
  • Publication number: 20220352403
    Abstract: A process for the preparation of colored solar cells or colored solar cell modules containing a colored polymer film with oriented effect pigments, and colored solar cells or colored solar cell modules prepared by this process.
    Type: Application
    Filed: April 29, 2022
    Publication date: November 3, 2022
    Applicant: MERCK PATENT GMBH
    Inventors: Marc HUNGER, Sebastian BARTH, Laurent DELOUX
  • Publication number: 20220348827
    Abstract: The present invention relates to a cholesteric liquid crystalline (LC) medium for a Polymer-Network Liquid Crystalline (PNLC) light modulation element, to a method of its production and to the use of such cholesteric LC media in PNLC light modulation elements. Furthermore, the present invention relates to PNLC light modulation elements, as such, to a method of their production, to the use of such light modulation elements in optic or electro optic devices, in particular in LC displays, and to optic or electro optic devices comprising such light modulation elements according to the present invention.
    Type: Application
    Filed: September 8, 2020
    Publication date: November 3, 2022
    Applicant: Merck Patent GmbH
    Inventors: Stephen MULCAHY, Eduardo BELTRAN GRACIA
  • Patent number: 11485786
    Abstract: The invention relates to the prophylaxis and/or treatment of fibrosis and/or fibrotic diseases by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from fibrosis and/or fibrotic diseases, including but not limited to systemic sclerosis (SSc). More specifically, the instant invention relates to the treatment of fibrotic diseases of the skin, lung, heart, liver and/or kidney by means of said antibody. Even more specifically, the instant invention relates to the administration of a recombinant, de-immunized monoclonal antibody targeting ?v-integrins patients suffering from systemic sclerosis, including, but not limited to systemic sclerosis of the skin, lung, heart and/or kidney by means of the anti-alpha-v integrin antibody DI17E6 and structural mutants or modifications thereof.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: November 1, 2022
    Assignee: Merck Patent GmbH
    Inventors: Ilhan Celik, Eike Staub, Miriam Urban, Sabine Raab, Eileen Samy, Andrew Bender, Georgianna Higginbotham, Yin Wu, Daigen Xu
  • Patent number: 11485723
    Abstract: The present invention relates to dibenzofuans and dibenzothiophenes thiophenes of formula I in which the occurring groups and parameters have the meanings as indicated in claim 1, to liquid-crystalline media comprising same and to high-frequency components comprising these media, especially microwave components for high-frequency devices, such as devices for shifting the phase of microwaves, in particular for microwave phased-array antennas.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: November 1, 2022
    Assignee: MERCK PATENT GMBH
    Inventors: Dmitry Ushakov, Beate Schneider, Carsten Fritzsch, Dagmar Klass
  • Publication number: 20220340810
    Abstract: The present invention relates to semiconducting nanoparticle.
    Type: Application
    Filed: September 10, 2020
    Publication date: October 27, 2022
    Applicant: MERCK PATENT GMBH
    Inventors: Sanaa KHALIL, Kobi Yaacov Netanel ODED
  • Patent number: 11479681
    Abstract: Effect pigments based on Al2O3 flakes with high weather resistance and less photoactivity and to their use thereof in paints, industrial coatings, automotive coatings, printing inks, cosmetic formulations. The effect pigments have a ratio of the amount by weight of Al2O3 of the Al2O3 flake and the amount by weight of the metal oxide(s) of the coating layer(s) in the range of from 27:73 to 83:17 based on the total weight of the effect pigment.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: October 25, 2022
    Assignee: Merck Patent GmbH
    Inventors: Sabine Schoen, Michael Jungnitz, Stefan Schlueter, Kirsten Fritsche, Carsten Plueg, Stephanie Andes, Ulrich Schoenefeld
  • Patent number: 11478459
    Abstract: The present invention relates to a solid pharmaceutical preparation of 3-Fluoro-4-[7-methoxy-3-methyl-8-(1-methyl-1H-pyrazol-4-yl)-2-oxo-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl]-benzonitrile, a method of making same, and medical uses thereof.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: October 25, 2022
    Assignee: Merck Patent GmbH
    Inventors: Simon Geissler, Stefan Schiller, Meike Harms, Holger Kubas, Markus Weigandt, Michael Lange
  • Publication number: 20220331430
    Abstract: The present invention relates to compositions of highly concentrated protein formulations showing reduced viscosity, which is induced by the addition of at least camphorsulfonic acid. The contained proteins in the prepared formulations are stabilized against aggregation and denaturation and are thus sufficiently storage-stable until administration to the patient.
    Type: Application
    Filed: September 16, 2020
    Publication date: October 20, 2022
    Applicant: MERCK PATENT GMBH
    Inventors: Tobias ROSENKRANZ, Raphael Johannes GUEBELI, Tanja HENZLER, Alexandra KROG, Christian HILDEBRANDT
  • Publication number: 20220332956
    Abstract: The present invention relates to a composition and to a method of manufacturing a composition.
    Type: Application
    Filed: June 28, 2022
    Publication date: October 20, 2022
    Applicant: MERCK PATENT GMBH
    Inventors: Denis GLOZMAN, Ehud SHAVIV, Yuki HIRAYAMA, Teruaki SUZUKI, Christian-Hubertus KUECHENTHAL
  • Patent number: 11473014
    Abstract: A LC lens and a liquid-crystal medium used in said LC lens, wherein the medium contains one or more compounds of each of formulae I and II
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: October 18, 2022
    Assignee: MERCK PATENT GMBH
    Inventors: Arnold (Jer-Wei) Chang, Roger (Chih-chieh) Chang, Ray (Kuang-Ting) Chou
  • Publication number: 20220325181
    Abstract: A liquid-crystalline medium which comprises at least one compound selected from the group of compounds of the formulae IA to IH, in which Z1 denotes a single bond, —CH2CH2—, —CH?CH—, —CH2O—, —OCH2—, —CF2O—, —OCF2—, —COO—, —OCO—, —C2F4—, —(CH2)4—, —CHFCHF—, —CF2CH2—, —CH2CF2—, —C?C—, —CF?CF—, —CH?CHCHO— or —CH2CF2O—, and the use thereof for an active-matrix display, in particular based on the VA, PSA, PS-VA, PALC, FFS, PS-FFS, SA-VA, PS-IPS or IPS effect.
    Type: Application
    Filed: February 3, 2021
    Publication date: October 13, 2022
    Applicant: Merck Patent GmbH
    Inventors: Harald HIRSCHMANN, Monika BAUER, Martina WINDHORST, Marcus REUTER, Kristin WEISS
  • Publication number: 20220325180
    Abstract: A liquid-crystalline medium which comprises at least one compound selected from the group of compounds of the formulae IA to IH, in which Z1 denotes a single bond, —CH2CH2—, —CH?CH—, —CH2O—, —OCH2—, —CF2O—, —OCF2—, —COO—, —OCO—, —C2F4—, —(CH2)4—, —CHFCHF—, —CF2CH2—, —CH2CF2—, —C?C—, —CF?CF—, —CH?CHCHO— or —CH2CF2O—, and the use thereof for an active-matrix display, in particular based on the VA, PSA, PS-VA, PALC, FFS, PS-FFS, SA-VA, PS-IPS or IPS effect.
    Type: Application
    Filed: January 29, 2021
    Publication date: October 13, 2022
    Applicant: Merck Patent GmbH
    Inventors: Harald HIRSCHMANN, Monika BAUER, Martina WINDHORST, Marcus REUTER, Kristin WEISS
  • Patent number: 11466213
    Abstract: The invention relates to a liquid-crystalline medium having negative dielectric anisotropy comprising one or more compounds of formula I and one or more compounds selected from the group of the compounds of the formulae IIA, IIB and IIC, wherein the groups and parameters have the meanings indicated in claim 1, to a guest-host liquid crystal medium derived therefrom comprising one or more dichroic dyes and the use of said medium in devices such as light shutters, switchable windows, switchable mirrors and guest-host displays. The invention further relates to devices containing the liquid crystalline medium according to the invention.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: October 11, 2022
    Assignee: Merck Patent GmbH
    Inventors: Jung-Min Lee, Hyun-Woo Bae, Dong-Mee Song, Yong-Kuk Yun
  • Patent number: 11466021
    Abstract: The present invention relates to compounds suitable for use in electronic devices, and to electronic devices, especially organic electroluminescent devices, comprising these compounds.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: October 11, 2022
    Assignee: MERCK PATENT GMBH
    Inventors: Amir Parham, Dominik Joosten, Aurélie Ludemann, Tobias Grossmann, Jonas Kroeber, Christian Eickhoff
  • Patent number: 11467169
    Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. It relates more particularly to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used as biomarkers for the diagnosis, pre-treatment of patients and during therapy of cartilage disorders. The invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment or during the treatment. It could be used for selecting/identifying subjects to be treated according to specific doses and/or dosing regimens by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk-benefit ratio in subjects.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: October 11, 2022
    Assignee: MERCK PATENT GMBH
    Inventors: Christoph H. Ladel, Hans Guehring, Anne-Christine Bay-Jensen, Morten Karsdal, Per Qvist